PYXS · NASDAQ
Pyxis Oncology, Inc.
$1.68 -0.02 (-0.88%)
Company overview
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for the treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates include PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $106M
- Employees
- 44
- Headquarters
- Boston, MA
- Website
- pyxisoncology.com
- CEO
- Thomas Civik
- Listed
- October 8, 2021
- P/E
- -1.30
- Dividend yield
- 0.00%
Company financials
- Revenue
- $13.9M
- Gross profit
- $13.8M
- Operating income
- -$85.9M
- EBITDA
- -$80M
- Net income
- -$81.7M
- EPS
- -$1.31
- Total assets
- $64.3M
- Total debt
- $18.3M
- Gross margin
- 99.81%
- Net margin
- -589.80%
- Earnings yield
- -77.06%
No geographic segmentation.
Showing FY 2025
PYXS
1D
NASDAQ
O1.66H1.72L1.65C1.70+0.02 (+0.89%)Vol141.52K